Intraductally administered pegylated liposomal doxorubicin reduces mammary stem cell function in the mammary gland but in the long term, induces malignant tumors
Yong Soon Chun, Saraswati Sukumar(Johns Hopkins University), Vered Stearns(Johns Hopkins University), Takahiro Yoshida(Osaka Prefecture University), Zhe Zhang(University Gastroenterology), Tsuyoshi Mori(Johns Hopkins University), David L. Huso(Johns Hopkins University), Richard J. Jones(Johns Hopkins University), Brandy Perkins(Johns Hopkins University)
Cited by 24
Related Papers
The Genomic Landscapes of Human Breast and Colorectal Cancers
|Science|2007|2.8k
Molecular Definition of Breast Tumor Heterogeneity
|Cancer Cell|2007|1.4k
CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment
|JNCI Journal of the National Cancer Institute|2005|947
VENOOCCLUSIVE DISEASE OF THE LIVER FOLLOWING BONE MARROW TRANSPLANTATION
|Transplantation|1987|914
Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine
|JNCI Journal of the National Cancer Institute|2003|850